The intrinsic substrate specificity of the human tyrosine kinome.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
Phosphorylation of proteins on tyrosine (Tyr) residues evolved in metazoan organisms as a mechanism of coordinating tissue growth1. Multicellular eukaryotes typically have more than 50 distinct protein Tyr kinases that catalyse the phosphorylation of thousands of Tyr residues throughout the proteome1-3. How a given Tyr kinase can phosphorylate a specific subset of proteins at unique Tyr sites is only partially understood4-7. Here we used combinatorial peptide arrays to profile the substrate sequence specificity of all human Tyr kinases. Globally, the Tyr kinases demonstrate considerable diversity in optimal patterns of residues surrounding the site of phosphorylation, revealing the functional organization of the human Tyr kinome by substrate motif preference. Using this information, Tyr kinases that are most compatible with phosphorylating any Tyr site can be identified. Analysis of mass spectrometry phosphoproteomic datasets using this compendium of kinase specificities accurately identifies specific Tyr kinases that are dysregulated in cells after stimulation with growth factors, treatment with anti-cancer drugs or expression of oncogenic variants. Furthermore, the topology of known Tyr signalling networks naturally emerged from a comparison of the sequence specificities of the Tyr kinases and the SH2 phosphotyrosine (pTyr)-binding domains. Finally we show that the intrinsic substrate specificity of Tyr kinases has remained fundamentally unchanged from worms to humans, suggesting that the fidelity between Tyr kinases and their protein substrate sequences has been maintained across hundreds of millions of years of evolution.
Description
Acknowledgements: We thank M. J. Begley, F. M. White, G. Getz, S. R. Hubbard, N. Shah and M. L. Hemming for discussions; and Y. Ma, M. R. Lundquist, K. Liberatore, T. M. Levy, S. A. Beausoleil, J. Wong, S. Petovic, M. Tran and the staff at Signalchem Biotech for technical assistance. T.M.Y.-B. thanks D. Yaron-Barir, S. Yaron, N. Yaron, J. R. Haddad and S. Haddad for their support. J.L.J. thanks M. Bak-Johnson, C. Ahn, S. Bak, J. W. Erickson and R. A. Cerione for their support. This research was supported by Leukemia & Lymphoma Society Award (to J.L.J. and L.C.C.); the Claudia Adams Barr Program for Cancer Research Award (to J.L.J.); National Institute of Health grants P01 CA120964 (to L.C.C.), R35-CA197588 (to L.C.C.), P01-CA117969 (to L.C.C.), R35-ES028374 (to M.B.Y.), R01-CA226898 (to M.B.Y.), R01-GM135331 (to B.E.T.) and R01-GM104047 (to B.E.T. and M.B.Y.); the joint Cancer Research UK and Brain Tumour Charity funded Brain Tumour Award C42454/A28596 (to M.B.Y.); the Charles and Marjorie Holloway Foundation (to M.B.Y.); the MIT Center for Precision Cancer Medicine (to M.B.Y.); the Jane Coffin Childs Memorial Fund (to J.M.O.); the Howard Hughes Medical Institute Hanna H. Gray Fellow award (to J.M.O.); and Cancer Research UK grants C9685/A26398 (to P.C.) and C9545/A29580 (to P.C.).
Journal Title
Conference Name
Journal ISSN
1476-4687